ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014

Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer.

I F Tannock et al.PubMed ↗Publisher ↗

No numbers read from the abstract.